{"disease":{"id":"mn","name":"mn"},"drugs":{"marketed":[{"drug_id":"temazepam","indication_name":"Short-term treatment of insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Restoril","generic_name":"temazepam","company_name":"Mallinckrodt","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"silver-nitrate","indication_name":"Insomnia Symptom Relief","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"SILVER NITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"silver nitrate","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"temazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Restoril","generic_name":"temazepam","company_name":"Mallinckrodt","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"doxepin-hydrochloride","indication_name":"Insomnia with sleep maintenance difficulty","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXEPIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"H1 receptor","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Doxepin may help maintain sleep by blocking H1 receptors."},{"drug_id":"barbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Veronal","generic_name":"BARBITAL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"barbital","quality_score":null,"revenue":null,"mechanism":"Veronal works by enhancing the effects of the neurotransmitter GABA, which helps to calm the brain and induce sleep."},{"drug_id":"rilmazafone","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhythmy","generic_name":"RILMAZAFONE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"rilmazafone","quality_score":19,"revenue":null,"mechanism":"RILMAZAFONE works by binding to the benzodiazepine receptor, enhancing the activity of the neurotransmitter GABA."},{"drug_id":"diazepam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valium","generic_name":"diazepam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Adenosine receptor A3, Aldo-keto reductase family 1 member C1, Aldo-keto reductase family 1 member C2","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"midazolam-hydrochloride","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"Midazolam Hydrochloride","company_name":"Takeda Pharmaceutical Company Limited","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-5/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":58,"revenue":null,"mechanism":""},{"drug_id":"zolpidem","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ambien","generic_name":"zolpidem","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"α1 subunit containing GABA A receptors","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Zolpidem binds to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing chloride channel opening and inhibiting neuronal excitation."},{"drug_id":"zolpidem","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ambien","generic_name":"zolpidem","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"α1 subunit containing GABA A receptors","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Zolpidem binds to the benzodiazepine site of α1 subunit containing GABA A receptors, increasing chloride channel opening and inhibiting neuronal excitation."},{"drug_id":"midazolam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Versed","generic_name":"midazolam","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2","drug_class":"Benzodiazepine (short-acting)","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nitrazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neozepam","generic_name":"NITRAZEPAM","company_name":"","drug_phase":"discontinued","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"nitrazepam","quality_score":null,"revenue":null,"mechanism":"Neozepam works by enhancing the activity of the neurotransmitter GABA, which helps to calm down overactive brain activity."},{"drug_id":"dmae","indication_name":"insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dmae 1549","generic_name":"DMAE","company_name":"Professional Complementary Health Formulas","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"ethchlorvynol","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alvinol","generic_name":"ETHCHLORVYNOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"ethchlorvynol","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"ethchlorvynol","indication_name":"Severe Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alvinol","generic_name":"ETHCHLORVYNOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"ethchlorvynol","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"chloral-hydrate","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nycoton","generic_name":"CHLORAL HYDRATE","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"chloral hydrate","quality_score":null,"revenue":null,"mechanism":"Nycoton works by acting as a central nervous system depressant, slowing down brain activity to induce sleep or anesthesia."},{"drug_id":"doxefazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxans","generic_name":"DOXEFAZEPAM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"doxefazepam","quality_score":null,"revenue":null,"mechanism":"Doxefazepam works by enhancing the activity of a neurotransmitter called GABA, which helps to calm the brain and induce sleep."},{"drug_id":"nimetazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nimetazam","generic_name":"NIMETAZEPAM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"nimetazepam","quality_score":null,"revenue":null,"mechanism":"Nimetazepam works by enhancing the activity of the neurotransmitter GABA, which helps to calm the brain and induce sleep."},{"drug_id":"belsomra","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Belsomra","company_name":"National Institute on Drug Abuse (NIDA)","drug_phase":"phase_1","molecular_target":"Orexin receptor type 1, Orexin receptor type 2, Orexin receptor type 1","drug_class":"","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"benadryl","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Benadryl","company_name":"Brooke Army Medical Center","drug_phase":"discontinued","molecular_target":"Histamine H4 receptor, Solute carrier family 22 member 2, 5-hydroxytryptamine receptor 2A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"bat","indication_name":"Treatment of insomnia in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bat","generic_name":"bat","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"diphenhydramine","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Benadryl","generic_name":"diphenhydramine","company_name":"Johnson & Johnson (McNeil Consumer Healthcare)","drug_phase":"marketed","molecular_target":"Histamine H4 receptor, Solute carrier family 22 member 2, 5-hydroxytryptamine receptor 2A","drug_class":"First-generation antihistamine, Sedative","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"lorazepam","indication_name":"Induce Anterograde Amnesia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ativan","generic_name":"lorazepam","company_name":"Generic (originally Wyeth/Pfizer)","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver","drug_class":"Benzodiazepine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ethinamate","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valmid","generic_name":"ETHINAMATE","company_name":"Dista","drug_phase":"marketed","molecular_target":"","drug_class":"ethinamate","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"secbutabarbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"secbutabarbital","company_name":"","drug_phase":"unknown","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"lunesta","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Lunesta","company_name":"Walter Reed Army Medical Center","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1, Gamma-aminobutyric acid receptor subunit alpha-2, Gamma-aminobutyric acid receptor subunit alpha-3","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"choline","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitamin J","generic_name":"Choline","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"Central Nervous System Stimulant [EPC]","quality_score":13,"revenue":null,"mechanism":""},{"drug_id":"loprazolam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"LOPRAZOLAM","company_name":"","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"loprazolam","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"clomethiazole","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Emineurina","generic_name":"CLOMETHIAZOLE","company_name":"","drug_phase":"discontinued","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"clomethiazole","quality_score":0,"revenue":null,"mechanism":"Emineurina works by enhancing the activity of the neurotransmitter GABA, which helps to calm excessive brain activity."},{"drug_id":"methylpentynol","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Atemorin","generic_name":"methylpentynol","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"methylpentynol","quality_score":null,"revenue":null,"mechanism":"Atemorin works by affecting the brain's chemistry to promote relaxation and sleep."},{"drug_id":"aprobarbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Allonal","generic_name":"APROBARBITAL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"aprobarbital","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"butobarbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Butethal","generic_name":"butobarbital","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"butobarbital","quality_score":null,"revenue":null,"mechanism":"Butethal works by enhancing the activity of neurotransmitters in the brain, such as GABA, to produce sedative and anxiolytic effects."},{"drug_id":"carbromal","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bromadal","generic_name":"CARBROMAL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"carbromal","quality_score":null,"revenue":null,"mechanism":"Bromadal works by enhancing the activity of neurotransmitters in the brain that promote relaxation and sleep."},{"drug_id":"flutoprazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Restas","generic_name":"FLUTOPRAZEPAM","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"flutoprazepam","quality_score":null,"revenue":null,"mechanism":"Flutoprazepam works by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain."},{"drug_id":"metharbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metabarbital","generic_name":"METHARBITAL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"GABA-A receptor; anion channel","drug_class":"metharbital","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"zopiclone","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imovane","generic_name":"ZOPICLONE","company_name":"Sunovion Pharms Inc","drug_phase":"marketed","molecular_target":"GABA A receptor alpha-5/beta-2/gamma-2","drug_class":"zopiclone","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"methyprylon","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noctan","generic_name":"METHYPRYLON","company_name":"Roche","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"methyprylon","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ramelteon","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rozerem","generic_name":"RAMELTEON","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A","drug_class":"Melatonin Receptor Agonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Rozerem works by activating the melatonin receptor type 1A to regulate sleep-wake cycles."},{"drug_id":"estazolam","indication_name":"Severe Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prosom","generic_name":"ESTAZOLAM","company_name":"Abbott","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine [EPC]","quality_score":54,"revenue":null,"mechanism":""},{"drug_id":"eszopiclone","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lunesta","generic_name":"ESZOPICLONE","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"eszopiclone","quality_score":75,"revenue":null,"mechanism":"Lunesta works by enhancing the activity of a neurotransmitter called GABA, which helps calm the brain and promote sleep."},{"drug_id":"doxepin","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zonalon","generic_name":"DOXEPIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":80,"revenue":null,"mechanism":"Zonalon works by blocking histamine H1 receptors in the brain, which helps to reduce anxiety and itching, and improve mood."},{"drug_id":"flurazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dalmane","generic_name":"FLURAZEPAM","company_name":"","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"Benzodiazepine","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"aceprometazine","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Acepromethazine","generic_name":"ACEPROMETAZINE","company_name":"","drug_phase":"phase_2","molecular_target":"Histamine H1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Acepromethazine works by blocking histamine receptors in the brain to promote sleep."},{"drug_id":"daridorexant","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Quviviq","generic_name":"DARIDOREXANT","company_name":"Idorsia","drug_phase":"marketed","molecular_target":"Orexin receptor type 1","drug_class":"Orexin Receptor Antagonist [EPC]","quality_score":53,"revenue":null,"mechanism":"Quviviq works by blocking the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles."},{"drug_id":"amobarbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Amobarbitone","generic_name":"AMOBARBITAL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"amobarbital","quality_score":28,"revenue":null,"mechanism":""},{"drug_id":"pentobarbital","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nembutal Sodium","generic_name":"PENTOBARBITAL","company_name":"Oak Pharms","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"pentobarbital","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lemborexant","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dayvigo","generic_name":"LEMBOREXANT","company_name":"Eisai","drug_phase":"marketed","molecular_target":"Orexin receptor type 2","drug_class":"Orexin Receptor Antagonist [EPC]","quality_score":75,"revenue":null,"mechanism":"Dayvigo blocks the action of orexin, a neurotransmitter that helps regulate sleep-wake cycles."},{"drug_id":"modafinil","indication_name":"Hypersomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Provigil","generic_name":"modafinil","company_name":"Nuvo Pharms","drug_phase":"marketed","molecular_target":"D(2) dopamine receptor","drug_class":"Sympathomimetic-like Agent [EPC]","quality_score":80,"revenue":null,"mechanism":"Provigil works by increasing the activity of certain neurotransmitters in the brain, such as dopamine, to help regulate sleep-wake cycles."},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"pf-06939999-dose-escalation","indication_name":"Spinal muscular atrophy with two copies of a healthy SMN2 gene","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06939999 dose escalation","generic_name":"pf-06939999-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"zaleplon","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sonata","generic_name":"ZALEPLON","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"gamma-Aminobutyric Acid A Receptor Agonist [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"glutethimide","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Glimid","generic_name":"GLUTETHIMIDE","company_name":"Sandoz","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-3/gamma-2","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"rozerem","indication_name":"Initial insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Rozerem","company_name":"Northwestern University","drug_phase":"marketed","molecular_target":"Melatonin receptor type 1A, Melatonin receptor type 1B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prazepam","indication_name":"Insomnia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazene","generic_name":"PRAZEPAM","company_name":"Parke Davis","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":163,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04350866","title":"Enhancing Access to Insomnia (EASI) Care in VA PCMHI Clinics","phase":"","overall_status":"COMPLETED","enrollment_count":277920,"lead_sponsor_name":"VA Office of Research and Development","has_results":true},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT03313466","title":"Trial of Internet-Based Cognitive Behavioral Therapy for Insomnia","phase":"NA","overall_status":"COMPLETED","enrollment_count":136630,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT06788522","title":"The Effects of Orexin Antagonism on Fear Extinction in PTSD","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":40120,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT07286838","title":"Ciwujia Capsules/Compound Ciwujia Granules in the Treatment of Insomnia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Hui Zhu","has_results":false},{"nct_id":"NCT05074901","title":"Virtual Agents-based Digital Interventions to Improve Health","phase":"NA","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"University of Bordeaux","has_results":false},{"nct_id":"NCT06375447","title":"Intelligent Diagnosis and Treatment Model for Insomnia Disorder","phase":"","overall_status":"RECRUITING","enrollment_count":16000,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT06692842","title":"Interactive Technological Intervention to Improve Mental Health Symptoms in Primary Health Care","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":12400,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT03047369","title":"The Myelin Disorders Biorepository Project","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06238869","title":"Online Mental Health Interventions for Children and Adolescents (OMHICA)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":7000,"lead_sponsor_name":"Jiangsu Province Nanjing Brain Hospital","has_results":false},{"nct_id":"NCT03998020","title":"Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence","phase":"NA","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04443361","title":"Insomnia After the COVID-19 Pandemic","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"University of Oslo","has_results":false},{"nct_id":"NCT05966038","title":"ALS/MND Natural History Study Data Repository","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02452684","title":"Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients","phase":"","overall_status":"COMPLETED","enrollment_count":4876,"lead_sponsor_name":"Eisai Co., Ltd.","has_results":false},{"nct_id":"NCT06336525","title":"Adult Sleep Health in the Rural Appalachia and Mississippi Delta Region and Its Relationships With Cardiometabolic Health Disparities.","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3680,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06574373","title":"Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06669507","title":"The Sleep Clinic Outcome and Practice Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":3400,"lead_sponsor_name":"St. Olavs Hospital","has_results":false},{"nct_id":"NCT06376760","title":"Changes in Intravenous Anesthetic Drug Dosage in Insomnia Patients Undergoing Digestive Endoscopy","phase":"","overall_status":"RECRUITING","enrollment_count":3360,"lead_sponsor_name":"Beijing Tiantan Hospital","has_results":false},{"nct_id":"NCT07050121","title":"A Prospective Multi-Center Real-World Study of Ciwujia Capsules in the Treatment of Cancer-Related Insomnia","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Shanghai Municipal Hospital of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT06306092","title":"Promoting Teenage Sleep for Improved Mental Health and School Performance","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Kristianstad University","has_results":false},{"nct_id":"NCT04693182","title":"Health Promoting Work Schedules: The Effect of Abolishing Quick Returns","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2700,"lead_sponsor_name":"Norwegian Institute of Public Health","has_results":false},{"nct_id":"NCT06353100","title":"Chronic Pain in the General Population of Chile","phase":"","overall_status":"COMPLETED","enrollment_count":2365,"lead_sponsor_name":"Pontificia Universidad Catolica de Chile","has_results":false},{"nct_id":"NCT07439757","title":"AI-Powered Precision Decision-Making for Pancreatic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06414655","title":"Multicenter Prospective Cohort Study of Twin Maternal-Child Dyads in China","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT05008744","title":"Laser Photocoagulation of Communicating Vessels in Twin-to-Twin Transfusion Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT04846010","title":"Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"All Natural Medicine Clinic, LLC","has_results":false},{"nct_id":"NCT04325464","title":"A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1590,"lead_sponsor_name":"Pear Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05043753","title":"\"Fetal gRowth AbnorMality dEtection Trial\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":1566,"lead_sponsor_name":"University of Modena and Reggio Emilia","has_results":false},{"nct_id":"NCT04317742","title":"eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":1554,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT07136623","title":"Detecting Pulmonary Hypertension With the Eko CORE 500 Digital Stethoscope","phase":"","overall_status":"RECRUITING","enrollment_count":1513,"lead_sponsor_name":"Eko Devices, Inc.","has_results":false},{"nct_id":"NCT05456607","title":"Digital CBT for Insomnia and Depression","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Rochester","has_results":false},{"nct_id":"NCT06478628","title":"Insomnia in Patients Participating in Interdisciplinary Pain Rehabilitation","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"Norwegian University of Science and Technology","has_results":false},{"nct_id":"NCT06854497","title":"The Impact of Non-motor Symptom on the Outcome of Stroke Subjects","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Chiayi Christian Hospital","has_results":false},{"nct_id":"NCT01953601","title":"Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1454,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02988375","title":"Sleep to Prevent Evolving Affecting Disorders","phase":"NA","overall_status":"COMPLETED","enrollment_count":1385,"lead_sponsor_name":"Henry Ford Health System","has_results":true},{"nct_id":"NCT04900064","title":"Evaluation of Primary Care Behavioral Health (PCBH) With the Addition of Self-help CBT - A Randomized Multicenter Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":1242,"lead_sponsor_name":"Linnaeus University","has_results":false},{"nct_id":"NCT03322774","title":"Sleep To Reduce Incident Depression Effectively","phase":"NA","overall_status":"COMPLETED","enrollment_count":1237,"lead_sponsor_name":"Henry Ford Health System","has_results":false},{"nct_id":"NCT04595214","title":"Develop a Multi-disciplinary Approach for a Personalized Prenatal Diagnostics and Care for Twin Pregnancies","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Assaf-Harofeh Medical Center","has_results":false},{"nct_id":"NCT05543499","title":"Database of Monochorionic Pregnancies","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04451109","title":"Dilapan-S®: A Multicenter US E-registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Medicem Technology s.r.o.","has_results":false},{"nct_id":"NCT05453136","title":"Phase III Study of TS-142 in Patients with Insomnia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1155,"lead_sponsor_name":"Taisho Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06109363","title":"A Stepped Care Model to Deliver CBT-I in Community","phase":"NA","overall_status":"RECRUITING","enrollment_count":1100,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT01097616","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1023,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01097629","title":"Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1020,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02783729","title":"Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1006,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT07233148","title":"Healing ALS Registry Observational Study (HAROS)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Healing Advocates Registry and Ministry","has_results":false},{"nct_id":"NCT04806009","title":"Evaluating an Online Mindfulness-Based Intervention for Insomnia","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Central South University","has_results":false},{"nct_id":"NCT07132879","title":"Telehealth in MND-Research (TIM-R): A Research Database for MND","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of Sheffield","has_results":false},{"nct_id":"NCT02952820","title":"Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":971,"lead_sponsor_name":"Eisai Inc.","has_results":true},{"nct_id":"NCT03545191","title":"Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects With Insomnia Disorder","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":930,"lead_sponsor_name":"Idorsia Pharmaceuticals Ltd.","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}